| Literature DB >> 28500797 |
Emily G Pieracci1,2, Nicole Evert3, Naomi A Drexler2, Bonny Mayes3, Inger Vilcins3, Philip Huang4, Jill Campbell4, Casey Barton Behravesh2, Christopher D Paddock2.
Abstract
AbstractFlea-borne (murine) typhus is a global rickettsiosis caused by Rickettsia typhi. Although flea-borne typhus is no longer nationally notifiable, cases are reported for surveillance purposes in a few U.S. states. The infection is typically self-limiting, but may be severe or life-threatening in some patients. We performed a retrospective review of confirmed or probable cases of fatal flea-borne typhus reported to the Texas Department of State Health Services during 1985-2015. When available, medical charts were also examined. Eleven cases of fatal flea-borne typhus were identified. The median patient age was 62 years (range, 36-84 years) and 8 (73%) were male. Patients presented most commonly with fever (100%), nausea and vomiting (55%), and rash (55%). Respiratory (55%) and neurologic (45%) manifestations were also identified frequently. Laboratory abnormalities included thrombocytopenia (82%) and elevated hepatic transaminases (63%). Flea or animal contact before illness onset was frequently reported (55%). The median time from hospitalization to administration of a tetracycline-class drug was 4 days (range, 0-5 days). The median time from symptom onset to death was 14 days (range, 1-34 days). Flea-borne typhus can be a life-threatening disease if not treated in a timely manner with appropriate tetracycline-class antibiotics. Flea-borne typhus should be considered in febrile patients with animal or flea exposure and respiratory or neurologic symptoms of unknown etiology.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28500797 PMCID: PMC5417200 DOI: 10.4269/ajtmh.16-0465
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Figure 1.Texas counties with fatal flea-borne typhus by case count, 1985–2015.
Epidemiological and laboratory data of patients with confirmed or probable fatal flea-borne typhus in Texas, 1985–2015
| Patient (age/sex) | Ethnicity | Animal exposure | Flea exposure | Onset (month/year) | Days from onset to death | Case status | Reciprocal IgG IFA titer(s) to |
|---|---|---|---|---|---|---|---|
| 81/F | Hispanic | Yes | Unknown | June 1985 | 11 | Confirmed | 64, 1,024 |
| 67/M | Non-Hispanic | No | No | September 1986 | 17 | Probable | 256 |
| 36/M | Hispanic | Unknown | Unknown | June 1991 | 8 | Confirmed | ≥1,024 |
| 72/M | Hispanic | Unknown | Unknown | June 1995 | 34 | Confirmed | ≥1,024 |
| 73/F | Hispanic | Yes | Yes | December 1998 | 6 | Probable | 512 |
| 53/M | Hispanic | Unknown | Unknown | January 2007 | 6 | Confirmed | ≥1,024 |
| 36/M | Non-Hispanic | Yes | Yes | April 2012 | 13 | Confirmed | ≥4,096 |
| 50/M | Non-Hispanic | Yes | Unknown | May 2013 | 20 | Confirmed | ≥4,096 |
| 55/M | Hispanic | Yes | Yes | May 2013 | 14 | Probable | 256 |
| 84/F | Hispanic | Unknown | Unknown | November 2014 | 12 | Probable | 64 |
| 62/M | Unknown | Yes | Unknown | January 2015 | 9 | Probable | 256 |
IFA = indirect immunofluorescence antibody.
Reported exposure to: * opossum, † cat, ‡ dog.
Patient also had 1:40 titer to R. typhi by slide agglutination assay.
Patient also had a skin biopsy specimen positive for a typhus group Rickettsia sp.by immunohistochemical stain.
Patient also had a reciprocal IgM IFA titer of 512 on same date.
Patient also had a reciprocal IgM IFA titer of 2,048 on same date.
Figure 2.Histopathological and immunohistochemical appearance of a skin biopsy specimen from a patient with a fatal typhus group rickettsiosis.
Clinical characteristics of 11 patients with fatal flea-borne typhus in Texas, 1985–2015
| Patient (age/sex) | Fever | Thrombocytopenia | Elevated hepatic transaminases | Anorexia | Nausea/vomiting | Rash | Pneumonia | Headache | Coma | Cough | Encephalopathy | Pulmonary edema | Acute kidney injury | Meningitis | Vertigo | Acute respiratory distress syndrome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81/F | √ | √ | √ | √ | ||||||||||||
| 67/M | √ | √ | √ | √ | √ | |||||||||||
| 36/M | √ | √ | √ | |||||||||||||
| 72/M | √ | √ | √ | √ | √ | √ | ||||||||||
| 73/F | √ | √ | √ | √ | √ | |||||||||||
| 53/M | √ | √ | √ | √ | √ | √ | √ | |||||||||
| 36/M | √ | √ | √ | √ | √ | √ | √ | |||||||||
| 50/M | √ | √ | √ | √ | ||||||||||||
| 55/M | √ | √ | √ | √ | √ | √ | √ | √ | √ | |||||||
| 84/F | √ | √ | √ | √ | √ | √ | √ | √ | ||||||||
| 62/M | √ | √ | √ | √ | √ | √ | √ | |||||||||
| Total (%) | 11 (100) | 9 (82) | 7 (63) | 6 (55) | 6 (55) | 6 (55) | 3 (27) | 3 (27) | 3 (27) | 2 (18) | 2 (18) | 2 (18) | 2 (18) | 1 (9) | 1 (9) | 1 (9) |
Patients that received tetracycline-class antibiotic during hospitalization.
Patients that received sulfa drug before hospitalization.
Medical charts available for review.